AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33043304
Drug: 3 to
RxNorm normalized name: Melquin-3 Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 to 4 cycles of BEP chemotherapy (high-intensity cisplatin)
Trial: 33044566
Drug: Ensartinib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ensartinib (200 mg/100 μCi)
Trial: 33045316
Drug: Weekly paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly paclitaxel (wP) at 80 mg/m² for 6 weeks + Low-dose fractionated whole abdominal radiation therapy (LDFWART)
Trial: 33045496
Drug: Ocrelizumab 600-mg
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ocrelizumab 600-mg Dose 2 or 3 infused over approximately 2 hours (Cohort 1)
Trial: 33045496
Drug: Ocrelizumab 300-mg
RxNorm normalized name: ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ocrelizumab 300-mg Dose 1, Infusion 2 over approximately 1.5 hours (Cohort 2)
Trial: 35611270
Drug: Laser interstitial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser interstitial thermal therapy (LITT)
Trial: 33045994
Drug: Shifts from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shifts from low/high to middle category (L-M/H-M) for phosphorus
Trial: 33045994
Drug: Shifts from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shifts from middle to low/high category (M-L/M-H) for phosphorus
Trial: 33045994
Drug: Shifts from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shifts from low/middle to high category (L-H/M-H) for calcium
Trial: 33045994
Drug: Shifts from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shifts from low to middle category (L-M) for intact parathyroid hormone
Trial: 33046066
Drug: daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily oral pre-exposure prophylaxis (PrEP)
Trial: 33046066
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ART-VL plus PrEP
Trial: 33046513
Drug: Single intratumoral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intratumoral injection
Trial: 33046518
Drug: Geptanolimab (GB226)
RxNorm normalized name: Geptanolimab
DrugBank: Geptanolimab (DB16417)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Geptanolimab (GB226) administered intravenously at a dosage of 3 mg/kg every 2 weeks until disease progression or unacceptable toxicity.
Trial: 33046517
Drug: CC-90011 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-90011 at 60 mg once per week (RP2D)
Trial: 33046517
Drug: CC-90011 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-90011 at 120 mg once per week (NTD)
Trial: 33046517
Drug: CC-90011 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-90011 at 80 mg once per week (MTD)
Trial: 33046621
Drug: AMG 820
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 820 (1100 mg or 1400 mg) plus pembrolizumab (200 mg) intravenously every 3 weeks
Trial: 33046765
Drug: Antihypertensive medications
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive medications with a reduction in hsCRP levels of 40% or greater (responder group)
Trial: 33046765
Drug: Antihypertensive medications
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive medications with a reduction in hsCRP levels of less than 40% (non-responder group)
Trial: 33046868
Drug: Autologous NKT
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous NKT cells engineered to co-express a GD2-specific chimeric antigen receptor (CAR) with interleukin-15
Trial: 33046870
Drug: Preoperative immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative immunotherapy with anti-PD1 plus anti-CTLA4 antibodies
Trial: 33046998
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (LMWH) - enoxaparin, dosage based on weight, D-dimer levels, and clinical condition.
Trial: 33047248
Drug: IntraOmmaya antiGD2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IntraOmmaya antiGD2 monoclonal antibody
Trial: 33047329
Drug: Dose adjustments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose adjustments to 40 mg/day for IM patients and 80 mg/day for PM patients
Trial: 33047329
Drug: Dose increase
RxNorm normalized name: Incruse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose increase to 60 mg/day for PM patients
Trial: 33047816
Drug: Dental isolation
RxNorm normalized name: ISOLATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dental isolation combination system (Isolite)
Trial: 33048057
Drug: Remote titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remote titration facilitated by telemonitoring using a smartphone-based system
Trial: 33048057
Drug: Standard titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard titration program consisting of in-office visits
Trial: 33048203
Drug: Ravulizumab (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ravulizumab (loading dose on Day 1, maintenance doses every 4-8 weeks)
Trial: 33048619
Drug: Targeted therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted therapy antitumor activity in underexplored cancer types (specific treatments not detailed)
Trial: 33050804
Drug: Tyrosine kinase
RxNorm normalized name: Protein-tyrosine kinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tyrosine kinase inhibitors (TKIs) - sunitinib, pazopanib, sorafenib
Trial: 33051036
Drug: Dialectical Behavior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialectical Behavior Therapy (DBT) for 6 months
Trial: 33051234
Drug: Weekly community
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly community dance sessions designed for people with breathlessness, lasting 75 min, led by a trained community dance leader.
Trial: 33051264
Drug: Belimumab plus
RxNorm normalized name: Belimumab
DrugBank: Belimumab (DB08879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Belimumab plus standard therapy
Trial: 33051855
Drug: Montreal museum
RxNorm normalized name: BCG, live, Montreal strain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montreal museum of fine arts (MMFA) participatory art-based activities, one weekly structured workshop over a 3-month period.
Trial: 33052476
Drug: Delay to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delay to oral feeding
Trial: 33052556
Drug: Savolitinib 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Savolitinib 600 mg plus gefitinib 250 mg orally once daily
Trial: 33054114
Drug: Pediatric-inspired chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pediatric-inspired chemotherapy incorporating 6 doses of pegaspargase 2000 IU/m2
Trial: 33054130
Drug: CC variant
RxNorm normalized name: Valiant Barrier
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC variant
Trial: 33055233
Drug: Diabetic foot
RxNorm normalized name: Zostrix Diabetic Foot Pain
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diabetic foot ulcer prevention program with once-daily foot temperature monitoring
Trial: 33055274
Drug: Non-aspirin group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-aspirin group
Trial: 33057634
Drug: D-dimer testing
RxNorm normalized name: dimer dilinoleyl dimer dilinoleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-dimer testing followed by whole-leg compression ultrasonography (CUS) for patients with positive D-dimer (≥0.5 µg/mL)
Trial: 33058182
Drug: Surgical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical therapy (n=86)
Trial: 33058182
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy (n=68)
Trial: 33060077
Drug: Atezolizumab (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab (1200 mg every 3 weeks for three cycles)
Trial: 33060149
Drug: HX008 200
RxNorm normalized name: Immunoglobulin g4 (252-theronine,306-proline,432-alanine), anti-(human programmed cell death 1) (human-mus musculus monoclonal hx008 .gamma.4-chain), disulfide with human-mus musculus monoclonal hx008 .kappa.-chain, dimer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HX008 200 mg intravenously every 3 weeks plus irinotecan 160 mg/m²
Trial: 33060506
Drug: Osmotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osmotic therapy administration
Trial: 33061494
Drug: Mediterranean diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mediterranean diet plus naltrexone/bupropion medication (breast cancer survivor MeDiet+NB group)
Trial: 33061494
Drug: Mediterranean diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mediterranean diet plus naltrexone/bupropion medication (non-cancer MeDiet+NB group)
Trial: 33061500
Drug: Anthocyanins (320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anthocyanins (320 mg/day)
Trial: 33062236
Drug: Proprotein convertase
RxNorm normalized name: Proprotein convertase 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proprotein convertase subtilisin/kexin 9 inhibitor (PCSK9i) therapy
Trial: 33062627
Drug: YH4808 (novel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YH4808 (novel selective potassium-competitive acid blocker)
Trial: 33062629
Drug: Tofacitinib aspartate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib aspartate 7.13 mg (test formulation)
Trial: 33062629
Drug: Tofacitinib citrate
RxNorm normalized name: Tofacitinib Citrate
DrugBank: Tofacitinib (DB08895)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tofacitinib citrate 8.08 mg (reference formulation)
Trial: 33062947
Drug: Nivolumab 40 mg
RxNorm normalized name: nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab 40 mg every 2 weeks
Trial: 33063141
Drug: Bi-monthly questionnaires
RxNorm normalized name: bis-ethoxydiglycol succinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bi-monthly questionnaires covering SARS-CoV-2 symptoms, health, preventive behavior, and lifestyle information.
Trial: 33063185
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg doxorubicin (DOX) and 10 mg mitomycin C emulsified 1:2 with ethiodized oil (Lipiodol) during conventional transarterial chemoembolization (cTACE)
Trial: 33064988
Drug: Personalized neoantigen-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized neoantigen-based vaccine NEO-PV-01 plus PD-1 blockade
Trial: 39187749
Drug: Chronic migraine
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic migraine with medication overuse (CM-MO)
Trial: 33066794
Drug: One-month dual-antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-month dual-antiplatelet therapy (DAPT) followed by 23-month ticagrelor monotherapy
Trial: 33066794
Drug: 12-month DAPT
RxNorm normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-month DAPT followed by 12-month aspirin alone
Trial: 33067297
Drug: CC-1 bispecific
RxNorm normalized name: B-CELL MATURATION ANTIGEN (BCMA) CLUSTER OF DIFFERENTIATION 3 (CD3) BISPECIFIC MONOCLONAL ANTIBODY (MAB) ANTI-BCMA/ANTI-CD3 BISPECIFIC MAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-1 bispecific PSMAxCD3 antibody administered after prophylactic interleukin-6 receptor blockade with tocilizumab (8 mg/kg body weight).
Trial: 33067318
Drug: KTE-X19, an
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KTE-X19, an autologous anti-CD19 CAR T-cell therapy
Trial: 33067633
Drug: BAX 335
RxNorm normalized name: BAX 335
DrugBank: BAX 335 (DB17845)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAX 335 gene therapy (1 of 3 IV doses: 2.0 × 10^11; 1.0 × 10^12; or 3.0 × 10^12 vector genomes/kg)
Trial: 33067633
Drug: BAX 335
RxNorm normalized name: BAX 335
DrugBank: BAX 335 (DB17845)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAX 335 gene therapy
Trial: 33068284
Drug: Sunitinib (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib (50 mg orally for 4 weeks followed by 2 weeks off)
Trial: 33068794
Drug: Ramucirumab 10
RxNorm normalized name: ramucirumab 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramucirumab 10 mg/kg and Pembrolizumab 200 mg every 21 days for up to 35 cycles
Trial: 33069648
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of factors (Evolut TAV, TAV-sinus of Valsalva relation, implantation depth)
Trial: 33070260
Drug: sintilimab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sintilimab (200 mg) plus chemotherapy (pemetrexed 500 mg/m2)
Trial: 33070964
Drug: Highest quintile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highest quintile of fasting glucose (≥5.1 mmol/L)
Trial: 33070964
Drug: Highest 2-hour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highest 2-hour postload glucose quintile (≥6.9 mmol/L)
Trial: 33071013
Drug: Urinary 3-hydroxyisovaleryl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urinary 3-hydroxyisovaleryl carnitine (3-HIC) excretion
Trial: 33072090
Drug: Polymyxin B
RxNorm normalized name: Polymyxin B
DrugBank: Polymyxin B (DB00781)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Polymyxin B (bactericidal antibiotic)
Trial: 33072090
Drug: Clodronate (macrophage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clodronate (macrophage modulator)
Trial: 33072399
Drug: Chimeric antigen
RxNorm normalized name: Chimeric antigen receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chimeric antigen receptor T-cell therapy (CAR-T cell therapy)
Trial: 33072814
Drug: Prolonged low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prolonged low-dose methylprednisolone (MP)
Trial: 33073219
Drug: rBCG-N-RSV vaccine
RxNorm normalized name: N-ethylurea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rBCG-N-RSV vaccine
Trial: 33073527
Drug: Bevacizumab plus
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab plus original chemotherapy regimen
Trial: 33073527
Drug: Original chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Original chemotherapy regimen
Trial: 33073614
Drug: S-ICD implant
RxNorm normalized name: Synovex S Drug Implant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-ICD implant
Trial: 33074373
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection or vitreoretinal surgery with incision distance of 3.5-4.0 mm posterior to the limbus.
Trial: 33074401
Drug: Osilodrostat 10
RxNorm normalized name: osilodrostat 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osilodrostat 10 mg twice daily
Trial: 33074406
Drug: Combined use
RxNorm normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined use of opioids and sedatives
Trial: 33074941
Drug: Maintenance fluids,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance fluids, nutritional fluids, drug fluids
Trial: 33074941
Drug: Diuretics or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretics or renal replacement therapy
Trial: 33074941
Drug: Sodium administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium administration
Trial: 33074941
Drug: Potassium administration
RxNorm normalized name: Potassium
DrugBank: Potassium (DB14500)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium administration
Trial: 33075126
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy (DAPT) in ACS patients
Trial: 33075126
Drug: Single antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single antiplatelet therapy (SAPT) in ACS patients
Trial: 33075126
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy (DAPT) in SIHD patients
Trial: 33075126
Drug: Single antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single antiplatelet therapy (SAPT) in SIHD patients
Trial: 33075159
Drug: Oral repaglinide
RxNorm normalized name: Repaglinide
DrugBank: Repaglinide (DB00912)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral repaglinide
Trial: 33075159
Drug: Long-acting insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting insulin glargine
Trial: 33076864
Drug: Ziv-aflibercept intravitreal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziv-aflibercept intravitreal injection
Trial: 34320504
Drug: Vitamin K
RxNorm normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K antagonist (VKA) treatment
Trial: 33077867
Drug: Intensive chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive chemotherapy (IC)
Trial: 33077867
Drug: Non-intensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-intensive treatment
Trial: 33077867
Drug: Intensive chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive chemotherapy (IC) in 2007-2013 vs 1999-2006
Trial: 33078373
Drug: Formalin fixation
RxNorm normalized name: formalin
DrugBank: Formaldehyde (DB03843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Formalin fixation of tumor specimens after infusion of panitumumab-IRDye800CW (25 or 50 mg)
Trial: 33080003
Drug: CD8+ T
RxNorm normalized name: AUTOLOGOUS CD4+ AND CD8+ T CELLS, ENRICHED FROM PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMCS) TRANSDUCED WITH A NONREPLICATIVE SELF-INACTIVATING (SIN) LENTIVIRAL VECTOR ENCODING A CHIMERIC ANTIGEN RECEPTOR (CAR) CONSISTING OF THE HUMAN CD19-SPECIFIC SCFV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD8+ T cells and their cytotoxic effector molecules
Trial: 33080911
Drug: Trastuzumab Emtansine
RxNorm normalized name: Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab Emtansine (T-DM1) as second-line therapy
Trial: 33080911
Drug: Trastuzumab Emtansine
RxNorm normalized name: Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab Emtansine (T-DM1) as third-line therapy
Trial: 33080911
Drug: Trastuzumab Emtansine
RxNorm normalized name: Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab Emtansine (T-DM1) as fourth-line therapy or higher
Trial: 33082372
Drug: Direct-acting antivirals
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct-acting antivirals (DAAs) therapy, duration shortened in 11 of the 29 patients (38%)
Trial: 33083026
Drug: Ad26 vector-based
RxNorm normalized name: SARS-COV-2 (COVID-19) vaccine, vector - Ad26
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad26 vector-based vaccine (Ad26.COV2.S)
Trial: 33083561
Drug: Metformin as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin as adjunctive therapy
Trial: 33083661
Drug: Proton Beam
RxNorm normalized name: Beam
DrugBank: Tricyclazole (DB02891)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton Beam Therapy (PBT) reirradiation
Trial: 33083685
Drug: Remote, real-time
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remote, real-time activity-monitoring devices combined with daily electronic patient-reported outcome (ePRO) items.
Trial: 33083685
Drug: Standard HF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard HF assessment (e.g., 6-min walking distance [6MWD], blood biomarkers, Kansas City Cardiomyopathy Questionnaire [KCCQ], and echocardiography).
Trial: 33083853
Drug: Passeo-18 lx
RxNorm normalized name: LX-7101
DrugBank: LX-7101 (DB16009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Passeo-18 lx drug-coated balloon
Trial: 33084880
Drug: Torasemide, 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Torasemide, 5 mg daily for 16 weeks
Trial: 33084880
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (G allele)
Trial: 33085815
Drug: C-type lectin
RxNorm normalized name: An autologous chimeric antigen receptor (CAR) T-cell therapy engineered to express an antibody-derived single-chain variable fragment that recognizes C-type lectin-like molecule-1 (CLL-1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C-type lectin receptors (CLRs)
Trial: 33087142
Drug: Oral supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral supplementation with a fractionated marine lipid concentration standardized to 17-HDHA and 18-HEPE for 4 weeks
Trial: 33087333
Drug: Camrelizumab 200
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Camrelizumab 200 mg (for bodyweight ≥50 kg) or 3 mg/kg (for bodyweight <50 kg) every 2 weeks plus oral apatinib 250 mg daily